Do we need to do fluorescence in situ hybridization analysis in myelodysplastic syndromes as often as we do?

Dolors Costa1, Sandra Valera, Ana Carrió

  • 1Hematopathology Section, Hospital Clínic, Villarroel 170, 08036 Barcelona, Catalonia, Spain. dcosta@clinic.ub.es

Leukemia Research
|March 16, 2010
PubMed